Short Interest in MetaVia Inc. (NASDAQ:MTVA) Decreases By 53.4%

MetaVia Inc. (NASDAQ:MTVA) saw a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 160,464 shares, a decrease of 53.4% from the July 15th total of 344,566 shares. Approximately 3.1% of the company’s stock are sold short. Based on an average daily volume of 100,346 shares, the short-interest ratio is currently 1.6 days.

MetaVia Price Performance

NASDAQ MTVA traded up $0.03 on Friday, reaching $1.49. The stock had a trading volume of 69,155 shares, compared to its average volume of 91,237. MetaVia has a 12-month low of $0.97 and a 12-month high of $19.03. The business’s 50-day moving average price is $1.60 and its 200 day moving average price is $1.69.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08). On average, research analysts forecast that MetaVia will post -2.79 earnings per share for the current year.

Institutional Trading of MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC acquired a new position in shares of MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent filing with the SEC. 1.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a report on Tuesday, July 21st. HC Wainwright restated a “buy” rating on shares of MetaVia in a report on Friday, July 10th. Finally, Wall Street Zen raised shares of MetaVia to a “sell” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, MetaVia presently has a consensus rating of “Hold” and a consensus price target of $20.00.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.